Halozyme Therapeutics Sees FY24 EPS $3.65-$4.05 Vs $3.99 Est.; Revenue $935M-$1.015B Vs $989.87M Est.

Author: Benzinga Newsdesk | August 06, 2024 04:13pm

Financial Outlook for 2024

The Company is reiterating its financial guidance for 2024, which was increased on June 6, 2024 as a result of the new European patent for ENHANZE®. For the full year 2024, the Company expects:

• Total revenue of $935 million to $1,015 million, representing growth of 13% to 22% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED®. Revenue from royalties of $520 million to $555 million, representing growth of 16% to 24% over 2023.
• Adjusted EBITDA of $555 million to $615 million, representing growth of 30% to 44% over 2023.
• Non-GAAP diluted earnings per share of $3.65 to $4.05, representing growth of 32% to 46% over 2023. The Company's earnings per share guidance does not consider the impact of potential future share repurchases.

Posted In: HALO